GlassScriptPhysician profile
Karin W Buettner
NPI 1811971724
$1,023.08
in general payments reported to CMS, 2019-2025
16 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2021: $367 · 2022: $184 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $361.03 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $156.36 | 2021-2025 | |
| Abbvie INC. | $107.28 | 2019-2022 | |
| Lsi Solutions INC | $83.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $50.13 | 2019 | |
| Therapeuticsmd, INC. | $32.15 | 2019-2021 | |
| Exeltis, USA INC. | $30.86 | 2021-2022 | |
| Agile Therapeutics, INC. | $26.93 | 2021 | |
| Hologic Sales and Service, LLC | $22.59 | 2019 | |
| Smith+Nephew, INC. | $19.98 | 2025 | Regranex, Collagenase Santyl |
| Biohaven Pharmaceutical Holding Company LTD. | $19.46 | 2022 | |
| Renovia INC | $15.70 | 2021 | |
| Myovant Sciences INC. | $14.82 | 2022 | |
| Scynexis, INC. | $11.87 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Buettner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.